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Abstract: Background: One of the main chemotherapeutic drugs used on a routine basis in patients
with metastatic colorectal cancer ((m)CRC) is the topoisomerase-1 inhibitor, irinotecan. However, its
usefulness is limited by the pre-existing or inevitable development of resistance. The ATP-binding
cassette (ABC) transporter ABCG2/breast cancer resistance protein (BRCP) through its function in
xenobiotic clearance might play an important role in irinotecan resistance. With a goal to evaluate the
clinical significance of ABCG2 measurements, we here review the current literature on ABCG2 in
relation to irinotecan treatment in CRC patients. Results: Few studies have evaluated the association
between ABCG2 gene or protein expression and prognosis in CRC patients. Discordant results were
reported. The discrepancies might be explained by the use of different criteria for interpretation
of results in the immunohistochemistry studies. Only one large study evaluated the ABCG2
protein expression and efficacy of irinotecan in mCRC (CAIRO study, n = 566). This study failed
to demonstrate any correlation between ABCG2 protein expression in the primary tumor and
response to irinotecan-based treatment. We recently raised questions on how to evaluate ABCG2
immunoreactivity patterns, and the results in the CAIRO study might be influenced by using a
different scoring protocol than the one proposed by us. In contrast, our recent exploratory study of
ABCG2 mRNA expression in 580 patients with stage III primary CRC (subgroup from the randomized
PETACC-3 study) indicated that high ABCG2 tumor tissue mRNA expression might be predictive
for lack of efficacy of irinotecan. Conclusion: The biological role of ABCG2 in predicting clinical
irinotecan sensitivity/resistance in CRC is uncertain. In particular, the significance of ABCG2 cellular
localization needs to be established. Data concerning ABCG2 mRNA expression and prediction of
adjuvant irinotecan efficacy are still sparse and need to be confirmed.
Keywords: ABCG2; BCRP; colorectal cancer; irinotecan
1. Introduction
Colorectal cancer (CRC) has a high incidence and mortality worldwide. In 2012, CRC was
the second most prevalent cancer type in men (9%) and the third among women (8%) [1].
Approximately 15–25% of patients with CRC present with synchronous liver metastases. In addition,
nearly 50% of patients initially diagnosed with localized disease ultimately develop metastases [2].
Randomized clinical CRC trials have established the superiority of 5-fluorouracil (5-FU) in combination
with oxaliplatin or irinotecan in metastatic (m)CRC [3]. Moreover, a number of biologically active
substances targeting specific signaling pathways in cancer cells have been approved in the treatment of
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patients with CRC, e.g., cetuximab, panitumumab, and bevacizumab. Owing to these treatments, the
overall survival of mCRC patients has been significantly improved. However, initial or acquired tumor
drug resistance is still a common observation among mCRC patients, resulting in a high treatment
failure leading to a high mortality rate among these patients.
Irinotecan (CPT-11) is a derivative of camptothecin and its active metabolite is SN-38, which is
an inhibitor of topoisomerase 1, a nuclear enzyme needed for the replication and transcription of
supercoiled DNA [4,5]. Several cellular mechanisms of resistance to irinotecan have been reported.
Among these are reduced intracellular drug accumulation mediated by the ATP binding cassette (ABC)
efflux transporter ABCG2 encoded by the ABCG2 gene, also known as breast cancer resistance protein
(BRCP), the placental ABC transporter or mitoxantrone resistance-associated protein [6].
The human ABC proteins belong to one of the largest superfamily of transporters and are
divided into seven subfamilies, ABCA to ABCG, which comprise a total of 48 members (http://www.
genenames.org/genefamilies/ABC). Among these members, the three efflux transporters ABCB1
(P-glycoprotein), ABCC1 (the multidrug resistance protein 1 (MRP1)), and ABCG2 are recognized as
major contributors to multidrug resistance in human cancer cells [7].
ABCG2 processes a very broad substrate specificity that differs from, but substantially overlaps
with that of ABCB1 and ABCC1 [8]. More recently, ABCG2 has been recognized by the US Food and
Drug Administration (FDA) to be one of the key drug transporters involved in drug absorption and
elimination. We have recently shown that acquired resistance to SN-38 in human CRC and breast
cancer cell lines results in a major upregulation of the ABCG2 transcript and protein, and that the
specific inhibition of ABCG2 results in the re-sensitization of the resistant cells [9,10], which strongly
suggests a key role of this protein in SN-38 resistance.
With this review, we aim to determine the significance of ABCG2 measurement in predicting
clinical resistance to irinotecan in CRC patients.
2. Method
PubMed was searched independently by two authors (DN and JAP) using the following search
strategy: ABCG2 AND irinotecan; BCRP AND irinotecan; ABCG2 AND “colorectal cancer” OR
“colorectal neoplasms”; BCRP AND “colorectal cancer” OR “colorectal neoplasms” (four searches).
A total of 243 publications were identified. Abstracts from the annual meetings of the American
Society of Clinical Oncology (ASCO) were retrieved for relevant abstracts using the same search terms.
Articles fulfilling the following criteria were excluded: reviews, duplications, non-human studies,
pre-clinical studies, studies in other cancer types, studies not involving the ABCG2 gene or protein,
studies on the toxicity or efficacy of other drugs, and studies not published in English. The last search
was carried out in July 2017. Ultimately, 13 studies were included in this review.
3. ABCG2
ABCG2 was initially cloned from multidrug-resistant breast cancer cell lines and demonstrated
to confer resistance to chemotherapeutic agents such as mitoxantrone, topotecan, and SN-38 [11–13].
Since then, the number of substrates has been rapidly expanding to include other chemotherapeutic
drugs such as methotrexate and several tyrosine kinase inhibitors (TKI) (imatinib and gefitinib).
Notably, several drugs which are integral parts of the current treatment of CRC such as irinotecan and
5-FU are substrates of ABCG2 [14].
Physiological substrates include estrone-3-sulfate, 17β-estradiol 17-(β-D-glucuronide), and uric
acid. Additionally, a range of common dietary xenobiotics are also substrates [7]. Hundreds of
inhibitors with diverse chemical structures have been identified, including calcium channel blockers
and drugs like tamoxifen and omeprazole [15–17].
The cloning of ABCG2 cDNA from drug-selected cell clones and normal tissue has demonstrated
functional variations in the amino acid substitutions in the protein with unaltered substrate specificity
(for a comprehensive review, see Noguchi et al.) [18].
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In normal tissue, the ABCG2 protein is highly expressed in the apical membrane of the placental
syncytiotrophoblasts, the epithelium of the small intestine, colon, and rectum, and on the biliary
canalicular membrane of hepatocytes. Furthermore, the protein is expressed on the luminal membrane
of brain microvessel endothelial cells and, to lesser extent, on kidney proximal tubular cells. The tissue
localization suggests a crucial role in absorption, distribution, metabolism, and elimination (ADME) of
endogenous substances and xenobiotics. Today, it is clear that the protein plays a key role in ADME of
anticancer drugs [17].
The transporter is frequently expressed on malignant hematopoietic and lymphoid cells,
and evolving literature associates ABCG2 single nucleotide polymorphisms (SNPs) not only with
anti-cancer drug efficacy, but also with incidence of leukaemia [19]. ABCG2 is also known as a stem cell
marker in immature myeloid and leukaemia stem cells [20]. Interestingly, subpopulations of stem-like
cells expressing ABCG2 (side population) have been found in a wide range of solid tumors, including
head and neck cancer, breast-, lung-, ovarian-, pancreatic- and CRC [21,22]. These stem-like cells
have characteristics of stem cells, e.g., quiescence, drug resistance, enhanced self-renewal capacity,
and tumorigenicity. The role of ABCG2 in drug resistance in this subpopulation of cells is currently
under investigation [23]. In CRC, Wnt signaling has been found to expand this side population in
SW480 cells in vitro. These side population cells expressed both ABCG2 and ABCB1 and displayed
resistance to 5-FU and SN-38 [24]. Finally, tumor cells isolated from 13 surgically resected colon tumors
and propagated as solid tumor spheroids in vitro have been shown to possess stem cell properties
including self-renewal, expression of ABCG2, and resistance to SN-38 [25].
4. ABCG2 Gene and Protein Expression in CRC; Findings Concerning Prognosis and Prediction
Studies concerning prognosis are given in Table 1. Recently, a cancer stem cell gene profile
including AGCG2 was found to predict relapse in 62 patients with stage II and III, radically resected
CRC receiving adjuvant chemotherapy with either single agent 5-FU (or capecitabine) or 5-FU (or
capecitabine) in combination with oxaliplatin [26], as patients (19%) with an unfavorable cancer
stem cell profile had a relapse-free survival of 22 months versus 43 months for patients (81%) with a
favorable profile.
Candeil et al. [27] investigated the expression of mRNA in normal colon tissue (eight samples),
primary CRC tumor tissue (10 samples), and CRC hepatic metastases (constituting 23 untreated, 12
after irinotecan-based therapy, and four after non-irinotecan chemotherapy). The tumors did not
seem to be matched. The study showed a significant decrease in the expression of ABCG2 mRNA
in the primary tumor tissue (about 100-fold compared with normal tissue), and about a five-fold
increase in ABCG2 mRNA expression in the metastases from irinotecan-treated patients. However, the
expression was still significantly lower than in normal colon mucosa cells (about 15-fold). This data
can be interpreted as primary colon cancer cells exhibiting an initial downregulation of ABCG2 mRNA
expression, suggesting that the downregulation of ABCG2 might be involved in the carcinogenesis
of CRC and, moreover, and that some primary CRC patients will benefit from adjuvant irinotecan
treatment (see below). Moreover, a change in ABCG2 expression may occur during the progression of
CRC (from primary to metastatic disease, which might be related to the systemic treatment applied).
Furthermore, a study of normal tissue and matched primary tumors from 13 CRC patients showed
that the ABCG2 mRNA was decreased six-fold in cancer tissue compared to matched normal CRC
mucosa. No significant correlation between ABCG2 mRNA expression and age, sex, race, grade or
stage of tumors, location, or treatment efficacy was established [28]. Finally, a study of ABCG2 mRNA
showed no significant difference in the expression in 21 patients with mucinous and 30 patients with
non-mucinous primary CRC, respectively. The number of patients with recurrent disease (17) was too
limited to perform subgroup analyses for patients receiving, e.g., irinotecan [29].
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Table 1. Studies of ABCG2 gene and protein expression in CRC in relation to expression pattern and/or prognosis.
Reference Setting Treatment Number ofPatients Methods
“Biomarker”
Investigated Findings Conclusions; Comments
Giampieri, et al. [26] Primary stage IIand III
5-FU/capecitabine
± oxaliplatin 62 Quantitative PCR
Panel of 66 genes
for “stemness”
including ABCG2
“Unfavorable cancer stem cell profile”
(19%): Relapse-free survival: 22 months
Favorable profile (81%): Relapse-free
survival 43 months
Expression levels of cancer stem cells
genes may be relevant for the prognosis;
ABCG2 among genes with high “weight”
Candeil, et al. [27]
Normal colon tissue
Primary tumour
Hepatic metastases
Untreated
Untreated
Irinotecan-based
therapy
Chemotherapy
without irinotecan
8
10
23
12
4
non-matched
Semi-quantitative
RT-PCR ABCG2 mRNA
Highly expressed
1/100 of normal colon tissue
Five-fold compared with primary tumor
NS from primary tumor
ABCG2 mRNA expression might be
upregulated by irinotecan treatment,
suggesting the potential involvement of
ABCG2 in irinotecan resistance
Gupta, et al. [28] Normal colon tissuePrimary tumour - 13 (matched)
Semi-quantitative
RT-PCR ABCG2 mRNA
6.6 ± 0.6-fold lower in cancer compared
to controls (p < 0.0001)
No correlation with grade or stage of
tumor, or with treatment
ACCG2 mRNA may have a role in
tumorigenesis, allowing the
accumulation of genotoxins and the
overproduction of nitric oxide
Glasgow, et al. [29] Primary, Dukes’stage C -
21 mucinous
30 nonmucinous RT-PCR ABCG2 mRNA
No difference in mucinous and
nonmucinous tumors
17 with recurrent disease; subset analysis
of patients receiving irinotecan not
possible
Liu, et al. [30] Primary - 60
IHC; whole
sections;
Multiclonal
antibody
ABCG2
36.7% of carcinomatous tissue; mainly
membranous expression
Correlation to lymph node metastases
ABCG2 may be important in the
progression and metastasis of CRC
Wang, et al. [31] Primary - 225
IHC; whole
sections; A mouse
monoclonal
antibody, BXP-21
ABCG2
83% positive cytoplasmic expression,
13% high 66% positive membranous
expression, 16% high
High membranous expression correlated
to shorter OS
Cytoplasmic expression not associated
with OS
Membranous ABCG2 expression is a
potential independent prognostic factor
Kang, et al. [32] Primary
88.5% received
5-FU-based
adjuvant
chemotherapy
234
IHC; TMA; a
rabbit polyclonal
antibody
ABCG2
78% positive cytoplasmic expression
62% positive membrane
High membranous expression associated
with better OS
Cytoplasmic expression not associated
with OS
Membranous ABCG2 expression is a
potential prognostic factor
5-FU: 5 Fluorouracil; CRC: colorectal cancer; IHC: immunohistochemistry; NS: not significant; PCR: polymerase chain reaction; RT-PCR: reverse transcription polymerase chain reaction;
OS: overall survival; TMA: tissue microarray.
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We recently published a paper on the analytical validation of anti-ABCG2 antibodies for
immunohistochemistry (IHC) on formalin-fixed paraffin-embedded tumor tissue [33]. This study
clearly showed that not all commercially available anti-ABCG2 antibodies are suited for IHC. Moreover,
based on the obtained results, we proposed a scoring protocol for ABCG2 immunoreactivity in CRC.
A Chinese study of ABCG2 protein expression analyzed with IHC (IHC; sparse information
about antibodies: multiclonal anti-ABCG2 antibody; a FOUR score system based on the intensity
of immunostaining and the number of positive cells was used, no separate scores for cytoplasmic
versus membrane immunostaining) and including 60 cases of primary CRC showed that ABCG2
positive cells were mainly positioned in the front of the carcinomatous tissue (the invasion front) or
between carcinomatous and non-carcinomatous margin tissue. ABCG2 was expressed in 36.7% of
carcinomatous tissue as compared to 3.3% in non-carcinomatous margin tissue (cell type not specified)
(p < 0.001). Furthermore, a high protein expression of ABCG2 was found in 30% of cases with lymph
node metastases compared to 6.7% in cases without positive lymph nodes (p < 0.025). The protein
was mainly expressed in the membranes of the cells. The results prompted the authors to suggest that
ABCG2 might be important in the progression of CRC [30].
A study by Wang et al. [31] investigated ABCG2 in 225 primary CRC tissues using IHC
(antibody mouse monoclonal antibody, BXP-21, Abcam Company, Cambridge, MA, USA; a FOUR
score system based on the intensity of immunostaining and the number of positive cells was used
with separate scores for cytoplasmic and membrane immunostaining). Totally, 83.1% of the cases
showed positive cytoplasmic expression, including 13.3% which were strongly positive, whereas 66.2%
showed positive membranous expression including 15.6% strongly positive. The strong membranous
staining significantly correlated to higher Dukes’ stage, more lymph nodes, and the presence of
distant metastases. Furthermore, membranous staining strongly correlated to a shortened survival
(Hazard Ratio (HR) 2.44, 95% Confidence Interval (CI) 1.05–5.65; p = 0.038) [31]. The cytoplasmic
expression levels were only correlated by increasing Dukes’ stage. Of note, clinical follow-up data was
only available for 69 patients (39.1%).
More recently, a Korean study by Kang et al. [32] examined 234 consecutive patients who
underwent surgical resection of primary CRC. ABCG2 expression was evaluated by IHC (antibody:
rabbit polyclonal antibody, Santa Cruz Biotechnology, Dallas, TX, USA; a scoring system based on
the intensity of immunostaining and the number of positive cells was used; the composite score was
dichotomized at the median with separate scores for cytoplasmic and membrane immunostaining)
and staining in the cytoplasm and membrane was more frequent in well-differentiated lesions and
was observed in 78% and 62% of the tumors, respectively. In contrast to the abovementioned study
by Wang, the study by Kang showed that high membranous expression of ABCG2 was significantly
associated with better overall survival (OS) (HR 0.62; 95% CI 0.41–0.95; p = 0.027) and disease-specific
survival (HR 0.50; 95% CI 0.31–0.81; p = 0.005), while cytoplasmic expression of ABCG2 was not
significantly associated with survival.
Only four studies investigated the ability of ABCG2 to predict sensitivity to irinotecan
(Table 2) [9,34–36]. Recently, we published an exploratory study of ABCG2 mRNA expression
(dichotomized by medium value) in 580 evaluable patients with colon cancer stage III enrolled in the
adjuvant PETACC-3 prospective randomized study [9,37]. This study enrolled 3278 patients and was
designed to evaluate the efficacy of the addition of adjuvant irinotecan to standard 5-FU/leucovorin.
The results strongly suggested a predictive role of tumor ABCG2 mRNA expression. The median
ABCG2 expression was used to split patients into “high” or “low” ABCG2 groups. The survival curves
showed a trend towards a significant separation in the irinotecan receiving patients, with ABCG2 levels
below the median being associated with a longer overall survival. However, such an association was
not observed in the patients treated with 5-FU only.
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Table 2. Studies of ABCG2 gene and protein expression in CRC in relation to the prediction of outcome after irinotecan-based therapy.
Reference Setting Treatment Number of Patients Methods “Biomarker”Investigated Findings Conclusions; Comments
Jensen, et al. [9] Primary stage IIand III
Randomized
phase III; 5-FU vs.
5-FU + irinotecan
688; statistical
analysis performed
on 580 stage III
Microarray gene
expression analysis ABCG2 mRNA
A separation of the survival curves by the
median ABCG2 mRNA expression in the
irinotecan receiving patients was observed,
while such a separation was not observed in
the 5-FU-only treated patients
A predictive role of tumour
ABCG2 mRNA expression is
strongly suggested
Silvestris, et al. [34] Metastatic, 1st line FOLFIRI 58
IHC; whole section;
mouse monoclonal
antibody BXP-21
ABCG2
56% high expression; no association to
clinicopathological characteristics; no
correlation to RR, TTP, OS
No predictive role for ABCG2
protein expression was found
Trumpi, et al. [35] Metastatic 1st or2nd line
Capecitabine,
irinotecan
(sequential or
combination;
CAIRO study)
566
IHC; TMA, mouse
monoclonal
antibody BXP-21
ABCG2
Response to irinotecan was not significantly
different in tumors with positive vs negative
expression of ABCG2. ABCG2 was not an
independent predictor of PFS
ABCG2 protein does not predict
response to irinotecan
Tuy, et al. [36] Metastatic, 1st line
Irinotecan-based
regimens
Other regimens
(not specified)
17
171
IHC; whole section;
mouse monoclonal
antibody BXP-21
ABCG2 Tumors with increased expression of ABCG2were significantly more resistant to irinotecan
Increased expression of ABCG2 is
an independent predictor of
SN-38 resistance (risk of
resistance increased 12-fold)
CRC: colorectal cancer; FOLFIRI: irinotecan + 5-FU + leucovorin; IHC: immunohistochemistry; PFS: progression-free survival; RR: response rate, OS: overall survival; TMA: tissue
microarray; TTP: time to progression; vs: versus.
Int. J. Mol. Sci. 2017, 18, 1926 7 of 16
A first-line study of 5-FU and irinotecan (FOLFIRI) in 58 patients with mCRC investigated the
association between ABCG2 protein expression determined by IHC (antibody: a mouse monoclonal
antibody, BXP-21, Abcam Company, Cambridge, MA, USA; a FOUR score system based on the intensity
of immunostaining and the number of positive cells was used with no separate score for membrane
versus cytoplasmic immunostaining) and clinical outcome. Furthermore, associations between
thymidylate synthase (TS), topoisomerase 1 (TOP 1), carboxylesterase (CES2) protein expression, and
clinical outcome were investigated. ABCG2 cytoplasmic expression was found in 56% of the patients,
with most positive tumor samples showing a membranous staining and some diffuse cytoplasmic
staining. No correlations with clinicopathological characteristics and ABCG2 expression (grading 0 + 1
versus 2 + 3) were demonstrated. Moreover, the expression of the protein did not affect response
rate (RR) (determined according to RECIST 1.1 [38]), time to progression (TTP), or OS. In addition,
ABCG2 protein expression was investigated in 19 synchronous liver metastases and 17 metastatic
lymph nodes, and no correlation between ABCG2 expression and primary tumors and metastatic
lesions was observed. Additional analyses revealed that only TS significantly correlated with clinical
outcome (RR, TTP, and OS) [34].
Trumpi et al. [35] investigated ABCG2 and ABCB1 protein expression in 566 patients with mCRC
included in the CAIRO study [39]. In this study, the authors analyzed tumor samples from patients who
received either first-line treatment with capecitabine, second-line irinotecan, and third-line capecitabine
plus oxaliplatin (sequential treatment; n = 410) or first-line treatment with capecitabine plus irinotecan
and second-line capecitabine plus oxaliplatin (combination treatment; n = 410). ABCG2 protein
expression was determined by IHC (ABCG2 antibody: a mouse monoclonal antibody, BXP-21, Abcam
Company, Cambridge, MA, USA; using a scoring system based on luminal membrane and cytoplasmic
expression, tissue microarray (TMA) with one core from each patient). The authors found no significant
difference with regard to response (determined according to RECIST 1.0 [40]) after the first cycle of
chemotherapy between ABGG2-positive and -negative tumors to either monotherapy (p = 0.879) or
combination therapy (p = 0.102) with irinotecan. In addition, a multivariate analysis showed that
ABCG2 expression was neither an independent predictor for progression-free survival (PFS) in patients
treated with irinotecan monotherapy (5.7 versus 6.1 months; p = 0.811) nor in patients treated with
capecitabine and irinotecan (9.0 versus 10.0 months; p = 0.196).
Finally, 189 patients who underwent colorectal resection were enrolled in a retrospective study
of ABCG2 protein expression determined by IHC (ABCG2 antibody: a mouse monoclonal antibody,
BXP-21, Abcam Company, Cambridge, MA, USA). Seventeen patients received irinotecan-based
chemotherapy for recurrent disease. In a multivariate logistic regression analysis, increased expression
of ABCG2 was an independent predictor of resistance to SN-38 (response evaluation was performed
according to RECIST 1.1 [38]). Furthermore, patients with increased levels of ABCG2 had shorter PFS
than patients with low levels (104 versus 242 days; p = 0.047) [36].
5. Studies on Inhibitors of ABCG2 in CRC
To date, many ABCG2 inhibitors with diverse chemical structures have been identified and the
list is continually growing [16]. Among these, Ko143, a highly potent analogue of fumetremorgin C1,
has been shown to re-sensitize human cancer cell lines with acquired SN-38 resistance and significant
upregulation of ABCG2 mRNA as well as to enhance the efficacy of irinotecan in ABCG2-expressing
CRC xenograft tumor models [41,42]. Yet, no clinical studies with Ko143 were identified. Although
most TKIs are competitive or high affinity substrates of ABCG2, some of them such as sorafenib,
sunitinib, lapatinib, erlotinib, gefitinib, imatinib, and nilotinib have been reported to be ABCG2
inhibitors or modulators [43–47]. These TKIs seem to inhibit the function of ABCG2 by directly
interacting with the substrate-binding sites, thus acting as competitive antagonists [48]. More recently,
afatinib has been shown to significantly inhibit the ATPase activity of ABCG2 and to downregulate the
mRNA and protein expression of the transporter [49]. Some of these TKIs appear also to be involved
in resistance mediated by ABCB1 (e.g., imatinib and nilotinib) [50,51].
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Table 3. Studies on inhibitors of ABCG2 in CRC.
Reference Treatment Phase Number of Patients Population Status DCR Median PFS(95%CI) (Months)
Median OS
(95%CI) (Months)
Mross, et al. [52] Irinotecan + sorafenib I 20 + 14 Various solid tumours, mCRC Completed 60%85% NR NR
Samalin, et al. [53] Irinotecan + sorafenib(NEXIRI) I/II 10 + 54
KRAS mutated mCRC; 2nd or
later lines (67% ≥ 3 prior lines) Completed
Phase I: 78
Phase II: 64.9 (51–77) Phase II: 3.7 (3.2–4.7) Phase II: 8.0 (4.8–9.7)
NCT01715441
Irinotecan or
sorafenib Irinotecan +
sorafenib (NEXIRI 2)
II,
randomized 160 planned
KRAS mutated mCRC, failure
of all known drugs Ongoing Estimated study completion: September 2015; no published data
NCT00839111 FOLFIRI + sorafinib II 43 planned mCRC, failure ofoxaliplatin-based therapy
Ongoing, not
verified since
September 2010
Estimated study completion: November 2010; no published data
NCT00889343
Irinotecan/oxaliplatin
+ sorafenib
Irinotecan/oxaliplatin
+ placebo
II,
randomized 101 planned mCRC, 2nd line Completed No published data
DCR: disease control rate; mCRC: metastatic colorectal cancer; NEXIRI: combined sorafenib and irinotecan; NR: not reported; PFS: progression-free survival; OS: overall survival.
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Mazard et al. used both in vitro and in vivo CRC models (nude mouse xenografts) to investigate
sorafenib in combination with SN-38 or irinotecan. Sorafenib did inhibit ABCG2-mediated transport
and enhanced intracellular drug accumulation, and thus increased the efficacy of irinotecan [54].
However, the authors concluded that the inhibition of ABCG2 was clearly not the only mechanism
involved in the synergy between sorafenib and irinotecan. Interestingly, sorafenib has also been
shown to improve the efficacy of irinotecan by inducing ABCG2 degradation in lysosomes and by the
inhibition of irinotecan-mediated p38 and extracellular signal-regulator kinase (ERK) activation [44,55].
Studies of inhibitors of ABCG2 are given in Table 3. A phase I, dose escalation study of sorafenib
in combination with irinotecan included 20 patients with refractory solid tumors in cohorts 1–3
(previous systemic therapy 90% of patients, previous topoisomerase 1 directed therapy not reported)
and 14 patients with mCRC in cohort 4 (prior irinotecan not reported) [52]. Stable disease was reported
in 60% of evaluable patients with solid tumors, and 77% of patients in the extended part of the
study (duration nor reported). One patient with mCRC had a partial response. However, prior to
the study, this patient had only received 5-FU and oxaliplatin. Sorafenib 100 or 200 mg BID had
no impact on the pharmacokinetics of irinotecan or its metabolite SN-38 as measured in plasma,
whereas sorafenib 400 mg two times a day significantly increased the area under the concentration
curve (AUC) of irinotecan and SN-38. This was not associated with increased toxicity. The authors
suggested that the increase of SN-38 concentration in the plasma was due to inhibition by sorafinib
of the formation of SN-38 glucuronide, since sorafenib strongly inhibited SN-38 glucuronidation in
human liver microsomes in vitro. No analysis of tumor tissue ABCG2 expression was performed [52].
NEXIRI was a phase I/II trial of sorafenib plus irinotecan as second- or later-line of treatment
in patients with KRAS-mutated mCRC. The phase II part of the trial included 54 mCRC patients
who had all progressed after irinotecan-based chemotherapy. Efficacy data were promising, with a
disease control rate (complete response + partial response + stable disease (duration not reported))
of 64.9% (95% CI 51–77%), a median PFS of 3.7 months (95% CI 3.2–4.7 months), and a median
survival (OS) of 8.0 months (95% CI 4.8–9.7 months). Toxicities included 37% grade 3 diarrhea,
13% grade 3 hand-foot syndrome, and 18% and 17% grade 3 and 4 neutropenia, respectively [53].
No pharmacokinetic analysis of irinotecan was performed. Furthermore, the expression of ABCG2
was not determined. Thus, the mechanism involved was not elucidated and further investigations are
needed. A randomized phase II study of irinotecan, sorafenib, and the combination of the two drugs is
ongoing (NEXIRI 2; ClinicalTrials.gov NCT01715441). In addition, two other phase II studies have
investigated the combination of FOLFIRI and sorafenib (NCT00839111) and sorafenib with FOLFOX
or FOLFIRI (NCT00889343). No data have yet been published.
6. Discussion
Overall, a very limited number of studies describing the association between ABCG2 or ABCG2
protein expression and irinotecan efficacy in CRC patients have been published. Two studies compared
the expression of ABCG2 mRNA in normal colon tissue and tumor tissue. Both studies showed
decreased expression in tumor tissue [27,28]. This finding prompted Gupta et al. to suggest that
ACCG2 could play a role in tumorigenesis by allowing the accumulation of genotoxins and the
overproduction of nitric oxide. However, both studies were small (13 and 62 patients) and the results
need to be confirmed in larger series.
Few studies evaluated the association between ABCG2 gene or protein expression and prognosis
in CRC patients. It is of note that different criteria for the interpretation of results in these IHC
studies were used (see below). One study found that high expression of stem cell markers including
ABCG2 correlated with poor patient prognosis [26], and another study found high expression of
ABCG2 to be correlated to the presence of lymph node metastases [30]. Two studies performed
separate assessment of membrane and cytoplasmic expression of ABCG2. One of these studies
found that high membranous expression of ABCG2 correlated with shorter OS [31]. In contrast, a
recent study found high membranous expression of the protein to be significantly associated with
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better OS [32]. A small study including only 10 primary tumors, 22 untreated hepatic metastases,
and 12 hepatic metastases obtained after irinotecan-containing chemotherapy showed increased
ABCG2 mRNA in hepatic metastases after exposure to irinotecan, suggesting a role of ABCG2 in
the development of acquired irinotecan resistance in vivo [27]. More recently, we published data on
ABCG2 mRNA expression and benefit (DFS and OS) in stage III colon cancer patients receiving an
adjuvant combination of 5-FU or 5-FU plus irinotecan [9]. This study suggested a predictive role
of tumor ABCG2 mRNA expression since a separation of the survival curves by the median ABCG2
mRNA expression in the irinotecan receiving patients was observed (patients with high ABCG2 mRNA
expression had a worse outcome), while such a separation was not observed in the 5-FU-only treated
patients. Since no difference was observed in the 5-FU-only treated patients, this study thus supported
the lack of a prognostic role of ABCG2. More importantly, the separation of the survival curves among
the patients receiving irinotecan pointed to a predictive utility of ABCG2 mRNA measurement in the
adjuvant irinotecan treatment of patients with colon cancer.
In contrast, a study evaluating the expression of ABCG2 protein and the efficacy of
irinotecan-based treatment in 58 patients with mCRC failed to demonstrate any correlation between
ABCG2 and outcome [34], and a study of ABCG2 and ABCB1 protein expression in 566 patients
from the prospective CAIRO study did not show any association between expression of the proteins
and response to irinotecan [35]. Furthermore, in the last study, neither ABCG2 nor ABCB1 were
independent predictors of PFS.
Overall, the role of ABCG2 as a prognostic factor or as predictor for irinotecan efficacy in CRC is
not well established. The few studies reported seemed to report discordant results.
Several explanations can be proposed for this lack of consistency. First of all, some studies
measured the ABCG2 mRNA expression [9], whereas other measured the ABCG2 protein expression
by applying the BXP21 antibody in IHC in either whole sections [34,36] or TMAs [35]. Moreover, the
study by Silvestris et al. [34] was not powered to detect any differences between protein expression and
drug effect. In the study by Trumpi et al., all included patients received irinotecan [35]. Only one study
complied with the recommendations put forward by Simon et al. [56] on the use of archived biopsies
for evaluating prognostic and predictive biomarkers. Thus, only the study by Jensen et al. [9] included
a control group not receiving irinotecan, allowing for distinction between prognostic and predictive
markers. Secondly, no validated assays and standardized reference values for ABCG2 IHC exist today.
Obviously, this leads to difficulties when comparing results, as most studies have used individual
cut-offs and varying assays to assess the protein expression. Furthermore, different locations of ABCG2
(basolateral/luminal versus cytoplasmic) may fundamentally influence the results. For many other
IHC tests, e.g., HER2, validated scoring protocols have been implemented. However, for ABCG2 IHC,
no such standard scoring protocols have yet been presented, although such uniform guidelines are a
prerequisite for comparing results from different clinical studies. In addition, tumor heterogeneity
might influence the results as some of the studies used TMAs. In analogy to P-glycoprotein (ABCB1),
it is likely that the different methods, including issues such as pre-analytical, analytical, post-analytical
variations, reproducibility, and sensitivity, that have been used to evaluate the expression levels and the
functional activity of ABCG2 may greatly contribute to the observed discrepancies in the monitoring
of ABCG2 expression [57–59]. Finally, it should also be noted that ABCG2 expression monitored by
mRNA or protein level may have limited reliability with respect to protein function and thus to the
cellular drug resistance [57].
All clinical studies but one focused on one transporter protein at a time, whereas it might be that
tumor cells depend on several drug transporters at the same time, executing their function in concert.
On the other hand, investigating both ABCG2 and ABCB1, Trumpi et al. did not find any correlation
between each of the ABC transporters or the combination of the two transporters and outcome [35].
Also, the protocol used for fixation, as well as the timing of biopsies differ from one study to another,
resulting in different exposures to chemotherapeutics which could influence the gene and protein
expressions. In particular, Trumpi et al. investigated a patient cohort in which irinotecan was used as
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the second-line therapy [35]. First-line (and adjuvant) therapy may have influenced the expression
level of ABCG2. Indeed, preclinical research has shown that 5-FU in combination with oxaliplatin
may alter the expression of these proteins [60]. Of note, Trumpi et al. evaluated the concordance of
ABCG2/ABCB1 expression in 17 primary tumors and their corresponding metastases and found a
mediocre to poor concordance. Finally, in vitro, it has been shown that ABCB1-mediated resistance
depends on transporter expression levels [61,62]. Most studies have found the expression of drug
transporters in clinical samples to be significantly lower than in drug-selected cell lines [63,64]. Thus,
the fact that the cancer cells express an increased level of the transporter does not automatically mean
that the transporter mediates significant resistance to the applied chemotherapy.
Currently, only one clinical phase I/II study aiming to overcome drug resistance by inhibiting
ABCG2 by sorafinib has been reported [53]. The phase II part of the trial included 54 mCRC
patients who were exposed to sorafinib plus irinotecan. All of the patients had previously failed
irinotecan treatment. Efficacy data were promising with a disease control rate of 65%, a median PFS of
3.7 months, and a median OS of 8.0 months. A randomized phase II is currently ongoing (NEXIRI 2;
ClinicalTrials.gov NCT01715441). Unfortunately, no test for the expression of ABCG2 prior to inclusion
is included and the role of ABCG2 might therefore not be elucidated.
In general, however, studies on inhibitors of ABC transporters have been disappointing [65].
In addition, the co-administration of ABCG2 inhibitors might increase the toxicity of irinotecan in
tissues which are protected by the physiological expression of ABCG2/ABC transporters. Notably,
it has recently been demonstrated that the inhibition efficiency of competitive inhibitors of ABCB1
depend on the expression level of ABCB1. Thus, cells expressing high levels of the transporter require
higher concentrations of competitive inhibitors to achieve the same reversal of the drug efflux [66].
These findings might also be applicable for ABCG2. When introducing novel ABCG2 inhibitors
into clinical testing, these drugs will be administered together with chemotherapy, e.g., irinotecan.
The potential increase in irinotecan toxicity in normal cells expressing ABCG2 efflux pumps (e.g.,
hepatocytes, brain-blood barrier cells), will always be of great concern. We presently have a novel
ABCG2 inhibitor in clinical trials (SCO-101) and, having successfully passed four clinical phase
1 studies as monotherapy, we are now preparing a clinical phase II study where the initial part will be
a run-in study consisting of a limited dose escalation study with increasing doses of SCO-101 and a
standard dose of chemotherapy [67]. Another important piece of information regarding normal tissue
toxicity when bypassing ABCG2 concerns studies where cancer patients have received novel types
of topoisomerase inhibitors that are not substrates for ABCG2 [68–70]. These phase 1 studies did not
show unexpected toxicities in normal tissue and thus support the idea of combining ABCG2 inhibitors
with standard chemotherapy. These findings might be also applicable for ABCG2.
ABCB1 and ABCG2 are known to act as components of the blood-brain barrier [71] and thus, if
effective inhibitors could be identified, might lead to increased drug uptake in the brain. Although
brain metastases are relatively infrequent in patients with gastrointestinal cancers, CRC patients with
RAS mutations have an increased incidence of brain metastases [72,73]. Finally, during the recent years,
evidence has mounted to indicate that many cancers including CRC display subpopulations of stem
cells that are responsible for tumor self-renewal. Such stem cells are characterized by the expression of
ABCG2 as well as other ABC transporters. Of specific interest is the inhibition of ABCG2 as means of
sensitizing cancer stem cells to chemotherapy, which is currently under investigation [17].
In conclusion, only a few studies have investigated the role of ABCG2 in CRC. The limited data
suggest that ABCG2 tumor cell expression might not be associated with patient prognosis. Two large
studies, one analyzing ABCG2 mRNA and adjuvant irinotecan treatment, the other investigating
the predictive value of ABCG2 protein/mRNA expression in mCRC patients receiving irinotecan
treatment, have shown contradictory results. A phase I/II study suggests that a TKI might increase
the efficacy of irinotecan, and the results of a subsequent randomized phase II are eagerly expected.
Based on this review, we conclude that the biological role of ABCG2 in clinical drug resistance is still
unknown, as is the clinical value of determining ABCG2 mRNA expression, and/or ABCG2 protein
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expression in relation to prognosis and drug prediction. However, before such studies are undertaken,
we suggest that international efforts be made to standardize ABCG2 measurements.
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